Project Information
Status:
Active
Page Last Updated:
05 November, 2026

 

Vulcan ePI Implementation Dashboard
GOAL: GLOBAL CRITICAL MASS

Critical mass is reached when 38 of 47 regulators implement FHIR ePI (Voluntary or Required)

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 implemented
Target: 38 of 47 regulators →
Goals at a glance

Where we stand against each goal

Critical-mass goal
1/38
implementing vs target
Target: ≥38 of 47 at Voluntary or Required
Required 1Voluntary 0Pilot 1Planning 2Exploring 7Not identified 36
# Goal Indicator Current Target Progress to target
1 Broaden regulatory engagement Regulators with any identified FHIR ePI activity 11 / 47 ≥38 (>80%)
 
29%
2 Move pilots into production Regulators at Pilot or beyond 2 / 47 ≥38 (>80%)
 
5%
3 Reach adoption critical mass
HEADLINE GOAL
Regulators at Voluntary or Required 1 / 47 ≥38 (>80%)
 
3%
4 Reach conversion critical mass Implementing regulators with >80% of their labels converted to ePI Not yet measured (1 regulator implementing) ≥38 regulators, each with >80% of labels converted Data not yet collected

Goals run in sequence: engage, pilot, adopt, then convert. Once a regulator adopts FHIR ePI, the next goal is for more than 80% of its labels to be available as ePI.

Key milestones

Regulatory dates to 2031

 
2026Now · Oct
Late 2026
EUEU voluntary ePI go-live
Phased voluntary go-live for centrally authorised products, per EMA’s draft ePI roadmap (March 2026). Submission guidance published September 2026.
Source ↗
2026
JOJordan FHIR ePI deadline
JFDA deadline for FHIR XML electronic leaflets.
▲ Source to be added
2027
2027
MYMalaysia FHIR timeline
NPRA roadmap step from PDF e-labelling toward FHIR-ready XML.
▲ Source to be added
2028
~2028
EUEU ePI mandatory for new authorisations
Revised EU pharmaceutical legislation expected to apply around 2028; ePI required for newly authorised medicines from that point.
Source ↗
2029
No milestones recorded
2030
No milestones recorded
2031
2031
EUEU ePI for all medicines
Already-authorised products move to ePI within three years, with the objective of ePI for all medicinal products by 2031.
Source ↗

Dates are as published by each regulator and may move. EU dates depend on the entry into force of the revised pharmaceutical legislation.

Every regulator, one tile

The 47-tile picture

JO
EU
EG
MY
BR
TW
ID
JP
TH
GB
US
DZ
AR
AM
AU
AZ
CA
CN
CO
CU
DO
SV
HK
IN
IR
IL
KZ
KW
LB
MX
MD
NZ
NG
PK
PY
PE
PH
KR
RU
SA
SG
ZA
CH
TN
TR
UA
UZ
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
← 38 needed at Voluntary or Required
Not identified (36)Exploring (7)Planning (2)Pilot (1)Voluntary (0)Required (1)

Hover a tile for the regulator name.

Pipeline

Where active regulators sit

Each column is a maturity stage; the goal is to move regulators to the right.

Exploring7
Discussion, consultation or early evaluation, proof-of-concept testing, synthetic data.
BRANVISA
Brazil
▲ Needs validation
TWTFDA
Chinese Taipei
▲ Needs validation
IDIndonesian FDA
Indonesia
▲ Needs validation
JPMHLW / PMDA
Japan
THThai FDA
Thailand
▲ Needs validation
GBMHRA
United Kingdom
▲ Needs validation
USFDA
United States
Planning2
Public commitment, documented, published timelines.
EGEDA
Egypt
▲ Needs validation
MYNPRA
Malaysia
Pilot1
Production use with real data and real submissions; formal and structured; putting systems together, running user acceptance testing, preparing for a production launch.
EUEC / EMA
European Union
Voluntary0
FHIR ePI can be used in production voluntarily.
No regulators yet
Required1
FHIR ePI is required.
JOJFDA
Jordan
What moves the needle

Next promotions to watch

Pilot → Voluntary
EUEuropean Union
Planning → Pilot
EGMYEgypt, Malaysia
Exploring → Planning
BRTWIDJPTHGBUSBrazil, Chinese Taipei, Indonesia, Japan, Thailand, United Kingdom, United States
Plus outreach to the 36 regulators not yet identified.
Transparent by design

Methodology

Not identified
Exploring
Planning
Pilot
Voluntary
Required
  1. Not identified: No public FHIR ePI activity identified.
  2. Exploring: Discussion, consultation or early evaluation, proof-of-concept testing, synthetic data.
  3. Planning: Public commitment, documented, published timelines.
  4. Pilot: Production use with real data and real submissions; formal and structured; putting systems together, running user acceptance testing, preparing for a production launch.
  5. Voluntary: FHIR ePI can be used in production voluntarily.
  6. Required: FHIR ePI is required.

Adoption critical mass. More than 80% of reference regulators implementing FHIR ePI (Voluntary or Required) in their jurisdiction: ≥38 of 47.

Conversion critical mass. After a regulator adopts FHIR ePI, more than 80% of its product labels are converted to ePI.

Denominator. A deduplicated working set of the regulatory authorities that are members or observers of the International Pharmaceutical Regulators Programme (IPRP) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Industry associations, international organizations and regional harmonization initiatives are excluded.

Evidence standard. Each placement should carry an official source, evidence date, scope, last-verified date. “Not identified” means no public FHIR ePI evidence was found in the sources used, not that a regulator is inactive.

Global FHIR ePI Adoption Tracker · HL7 FHIR Accelerator Vulcan · Status as of October 2026. Working statuses and denominator should be governed and periodically revalidated.